Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

BACKGROUND In patients with heart failure due to dilated cardiomyopathy, cardiac energy metabolism is impaired, as indicated by a reduction of the myocardial phosphocreatine-to-ATP ratio, measured noninvasively by 31P-MR spectroscopy. The purpose of this study was to test whether the phosphocreatine-to-ATP ratio also offers prognostic information in terms of mortality prediction as well as how this index compares with well-known mortality predictors such as left ventricular ejection fraction (LVEF) or New York Heart Association (NYHA) class. METHODS AND RESULTS Thirty-nine patients with dilated cardiomyopathy were followed up for 928+/-85 days (2.5 years). At study entry, LVEF and NYHA class were determined, and the cardiac phosphocreatine-to-ATP ratio was measured by localized 31P-MR spectroscopy of the anterior myocardium. During the study period, total mortality was 26%. Patients were divided into two groups, one with a normal phosphocreatine-to-ATP ratio (>1.60; mean+/-SE, 1.98+/-0.07; n=19; healthy volunteers: 1.94+/-0.11, n=30) and one with a reduced phosphocreatine-to-ATP ratio (<1.60; 1.30+/-0.05; n=20). At re-evaluation (mean, 2.5 years), 8 of 20 patients with reduced phosphocreatine-to-ATP ratios had died, all of cardiovascular causes (total and cardiovascular mortality, 40%). Of the 19 patients with normal phosphocreatine-to-ATP ratios, 2 had died (total mortality, 11%), one of cardiovascular causes (cardiovascular mortality, 5%). Kaplan-Meier analysis showed significantly reduced total (P=.036) and cardiovascular (P=.016) mortality for patients with normal versus patients with low phosphocreatine-to-ATP ratios. A Cox model for multivariate analysis showed that the phosphocreatine-to-ATP ratio and NYHA class offered significant independent prognostic information on cardiovascular mortality. CONCLUSIONS The myocardial phosphocreatine-to-ATP ratio, measured noninvasively with 31P-MR spectroscopy, is a predictor of both total and cardiovascular mortality in patients with dilated cardiomyopathy.

[1]  K Ugurbil,et al.  Bioenergetic abnormalities associated with severe left ventricular hypertrophy. , 1993, The Journal of clinical investigation.

[2]  G. Radda,et al.  Quantitative studies of human cardiac metabolism by 31P rotating-frame NMR. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Neubauer,et al.  Metabolic Consequences and Predictability of Ventricular Fibrillation in Hypoxia: A 31P– and 23Na–Nuclear Magnetic Resonance Study of the Isolated Rat Heart , 1992, Circulation.

[4]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[5]  J. Zweier,et al.  Bioenergetic consequences of cardiac phosphocreatine depletion induced by creatine analogue feeding. , 1991, The Journal of biological chemistry.

[6]  J. Ingwall,et al.  Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. , 1995, Circulation.

[7]  M. Packer.  Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure. , 1990, The American journal of cardiology.

[8]  J. B. Kneeland,et al.  Gated cardiac MR imaging and P-31 MR spectroscopy in humans at 1.5 T. Work in progress. , 1989, Radiology.

[9]  E. E. van der Wall,et al.  Cardiac metabolism in patients with dilated and hypertrophic cardio‐myopathy: Assessment with proton‐decoupled P‐31 MR spectroscopy , 1992, Journal of magnetic resonance imaging : JMRI.

[10]  Roger J. Ordidge,et al.  Image-selected in Vivo spectroscopy (ISIS). A new technique for spatially selective nmr spectroscopy , 1986 .

[11]  J. Ingwall,et al.  Creatine kinase system in failing and nonfailing human myocardium. , 1996, Circulation.

[12]  T. Inubushi,et al.  Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. , 1995, Circulation.

[13]  G. Radda,et al.  Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy , 1991, The Lancet.

[14]  B. Massie,et al.  Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. , 1985, The American journal of cardiology.

[15]  A. Sanbe,et al.  Regional energy metabolism of failing hearts following myocardial infarction. , 1993, Journal of molecular and cellular cardiology.

[16]  S. Neubauer,et al.  Long-term beta-blocker treatment prevents chronic creatine kinase and lactate dehydrogenase system changes in rat hearts after myocardial infarction. , 1996, Journal of the American College of Cardiology.

[17]  S. Neubauer,et al.  31P Magnetic Resonance Spectroscopy in Dilated Cardiomyopathy and Coronary Artery Disease: Altered Cardiac High‐Energy Phosphate Metabolism in Heart Failure , 1992, Circulation.

[18]  J. Cohn,et al.  Prognosis of congestive heart failure and predictors of mortality. , 1988, The American journal of cardiology.

[19]  J. Ingwall,et al.  Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. , 1996, Circulation research.

[20]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[21]  C. Hardy,et al.  Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. , 1991, American heart journal.

[22]  K. M. McDonald,et al.  Bioenergetic consequences of left ventricular remodeling. , 1995, Circulation.

[23]  J. Ingwall,et al.  Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. , 1996, Journal of molecular and cellular cardiology.

[24]  J. Ingwall,et al.  Inhibition of the creatine kinase reaction decreases the contractile reserve of isolated rat hearts. , 1995, The American journal of physiology.

[25]  S. Neubauer,et al.  Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. , 1995, European heart journal.

[26]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[27]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[28]  K. Clarke,et al.  Energetic correlates of cardiac failure: changes in the creatine kinase system in the failing myocardium. , 1990, European heart journal.

[29]  C. Hardy,et al.  Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. , 1990, The New England journal of medicine.

[30]  C. Higgins,et al.  Evaluation of the Hereditary Syrian Hamster Cardiomyopathy by 31P Nuclear Magnetic Resonance Spectroscopy: Improvement After Acute Verapamil Therapy , 1986, Circulation research.

[31]  C. Higgins,et al.  Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. , 1991, Radiology.

[32]  P A Bottomley,et al.  MR spectroscopy of the human heart: the status and the challenges. , 1994, Radiology.

[33]  M. Weiner,et al.  In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. , 1990, The American journal of cardiology.

[34]  K. Swedberg,et al.  Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. , 1980, British heart journal.

[35]  S. Neubauer,et al.  Preservation of left ventricular mechanical function and energy metabolism in rats after myocardial infarction by the angiotensin-converting enzyme inhibitor quinapril. , 1996, Journal of cardiovascular pharmacology.

[36]  M. Wyss,et al.  Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. , 1992, The Biochemical journal.

[37]  J. Ingwall.  Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. , 1982, The American journal of physiology.

[38]  B. Pitt,et al.  Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. , 1989, Journal of the American College of Cardiology.

[39]  Arend Heerschap,et al.  Skeletal muscles of mice deficient in muscle creatine kinase lack burst activity , 1993, Cell.

[40]  M. Laser,et al.  Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. , 1995, The Journal of clinical investigation.